B. Metzler seel. Sohn & Co. AG Has $689,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

B. Metzler seel. Sohn & Co. AG lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,044 shares of the company’s stock after purchasing an additional 245 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Neurocrine Biosciences were worth $689,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Pier 88 Investment Partners LLC raised its holdings in Neurocrine Biosciences by 51.8% during the fourth quarter. Pier 88 Investment Partners LLC now owns 4,690 shares of the company’s stock worth $640,000 after buying an additional 1,600 shares during the last quarter. AIA Group Ltd bought a new position in Neurocrine Biosciences in the 4th quarter valued at about $232,000. Wellington Management Group LLP boosted its stake in Neurocrine Biosciences by 102.9% during the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock valued at $198,939,000 after purchasing an additional 739,199 shares during the last quarter. Physician Wealth Advisors Inc. bought a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $66,000. Finally, Allstate Corp purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth approximately $397,000. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NBIX has been the subject of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. Morgan Stanley reiterated an “overweight” rating and issued a $150.00 target price (down previously from $185.00) on shares of Neurocrine Biosciences in a report on Friday, March 7th. Wedbush cut their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Wednesday, March 26th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.52.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $95.65 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $93.59 and a 1 year high of $157.98. The stock’s fifty day moving average price is $120.01 and its two-hundred day moving average price is $124.33. The company has a market cap of $9.54 billion, a P/E ratio of 29.07, a P/E/G ratio of 0.77 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences announced that its board has authorized a stock repurchase plan on Friday, February 21st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In related news, insider Ingrid Delaet sold 623 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $149.29, for a total transaction of $93,007.67. Following the sale, the insider now owns 3,442 shares of the company’s stock, valued at approximately $513,856.18. This represents a 15.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Julie Cooke sold 700 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total transaction of $82,796.00. Following the completion of the transaction, the insider now directly owns 18,831 shares of the company’s stock, valued at approximately $2,227,330.68. The trade was a 3.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 232,906 shares of company stock worth $33,869,030 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.